Page last updated: 2024-10-19

1-octanol and Essential Tremor

1-octanol has been researched along with Essential Tremor in 4 studies

1-Octanol: A colorless, slightly viscous liquid used as a defoaming or wetting agent. It is also used as a solvent for protective coatings, waxes, and oils, and as a raw material for plasticizers. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed)
octan-1-ol : An octanol carrying the hydroxy group at position 1.

Essential Tremor: A relatively common disorder characterized by a fairly specific pattern of tremors which are most prominent in the upper extremities and neck, inducing titubations of the head. The tremor is usually mild, but when severe may be disabling. An autosomal dominant pattern of inheritance may occur in some families (i.e., familial tremor). (Mov Disord 1988;13(1):5-10)

Research Excerpts

ExcerptRelevanceReference
"1-Octanol (an 8-C alcohol currently used as a food-flavoring agent) is known to inhibit tremor in essential tremor (ET) animal models at a much lower dose than ethyl alcohol."9.11Pilot trial of 1-octanol in essential tremor. ( Burstein, AH; Bushara, KO; Goldstein, SR; Grimes, GJ; Hallett, M, 2004)
"Twenty-one single oral doses of 1-octanol were given to patients with essential tremor (ET) in an open-label dose-escalation study."9.11Open-label dose-escalation study of oral 1-octanol in patients with essential tremor. ( Bushara, KO; Hallett, M; Mari, Z; Reich, M; Shill, HA, 2004)
" The half-life of OA was 87."6.76An open-label, single-dose, crossover study of the pharmacokinetics and metabolism of two oral formulations of 1-octanol in patients with essential tremor. ( Bowen, D; Buchwald, P; Dong, C; Grimes, GJ; Hallett, M; Haubenberger, D; Ippolito, D; Kalowitz, D; Nahab, FB; Potti, G; Starling, J; Toro, C; Wittevrongel, L, 2011)
"1-Octanol (an 8-C alcohol currently used as a food-flavoring agent) is known to inhibit tremor in essential tremor (ET) animal models at a much lower dose than ethyl alcohol."5.11Pilot trial of 1-octanol in essential tremor. ( Burstein, AH; Bushara, KO; Goldstein, SR; Grimes, GJ; Hallett, M, 2004)
"Twenty-one single oral doses of 1-octanol were given to patients with essential tremor (ET) in an open-label dose-escalation study."5.11Open-label dose-escalation study of oral 1-octanol in patients with essential tremor. ( Bushara, KO; Hallett, M; Mari, Z; Reich, M; Shill, HA, 2004)
" The half-life of OA was 87."2.76An open-label, single-dose, crossover study of the pharmacokinetics and metabolism of two oral formulations of 1-octanol in patients with essential tremor. ( Bowen, D; Buchwald, P; Dong, C; Grimes, GJ; Hallett, M; Haubenberger, D; Ippolito, D; Kalowitz, D; Nahab, FB; Potti, G; Starling, J; Toro, C; Wittevrongel, L, 2011)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (75.00)29.6817
2010's1 (25.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Nahab, FB1
Wittevrongel, L1
Ippolito, D1
Toro, C1
Grimes, GJ2
Starling, J1
Potti, G1
Haubenberger, D1
Bowen, D1
Buchwald, P1
Dong, C1
Kalowitz, D1
Hallett, M3
Bushara, KO2
Goldstein, SR1
Burstein, AH1
Shill, HA1
Mari, Z1
Reich, M1
Martin, FC1
Handforth, A1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor[NCT00102596]Phase 221 participants (Actual)Interventional2005-01-31Completed
Effects of Octanoic Acid for Treatment of Essential Voice Tremor[NCT01864525]Phase 1/Phase 217 participants (Actual)Interventional2013-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Blood Plasma Levels of Octanoic Acid After 64 mg/kg 1-Octanol Dose

Octanoic Acid is a metabolite of 1-octanol. Blood plasma levels of octanoic acid were measured at 5, 20, 45, 70, 100, 130, 160, 210, 270 and 360 minutes post-dose. (NCT00102596)
Timeframe: 5, 20, 45, 70, 100, 130, 160, 210, 270 and 360 minutes post-dose

,
Interventionng/ml (Mean)
Plasma Octanoic Acid Level at 5 min post-dosePlasma Octanoic Acid Level at 20 min post-dosePlasma Octanoic Acid Level at 45 min post-dosePlasma Octanoic Acid Level at 70 min post-dosePlasma Octanoic Acid Level at 100 min post-dosePlasma Octanoic Acid Level at 130 min post-dosePlasma Octanoic Acid Level at 160 min post-dosePlasma Octanoic Acid Level at 210 min post-dosePlasma Octanoic Acid Level at 270 min post-dosePlasma Octanoic Acid Level at 360 min post-dose
64 mg/kg 1-Octanol Cellulose-based (CEL) Formulation62.945064.127967.976788.585701.605448.234662.883179.102248.741266.37
64 mg/kg 1-Octanol Soybean Oil Embedded (SOY) Formulation74.163885.529645.5513315.269289.399605.686678.694307.742618.25872.51

Heart Rate Post 1-Octanol Dose

(NCT00102596)
Timeframe: 0 minutes, 15 minutes, 100 minutes and 24 hours post-dose

Interventionbeats per minute (Least Squares Mean)
Heart Rate at 0 minHeart Rate at 15 minHeart Rate at 100 minHeart Rate at 24 hours
1-Octanol Dose70.866.667.172.4

Normalized Mean Tremor Amplitude for Both Formulations of 64 mg/kg 1-Octanol in Part B

Spirography mean tremor amplitudes were measured in the right hand of each participant at 0, 15, 30, 60, 90, 120, 150, 180, 240 and 360 minutes post-dose. Then, the scores of each participant were normalized (i.e., divided by) by their baseline tremor severity scores so that all scores are expressed as a proportion of the baseline score. Therefore, 1 is the baseline tremor severity, and lower scores indicate tremor reduction. (NCT00102596)
Timeframe: 0, 15, 30, 60, 90, 120, 150, 180, 240 and 360 minutes post-dose

,
Interventionnormalized score on a scale (Mean)
Normalized score at 0 minutesNormalized score at 15 minutes post-doseNormalized score at 30 minutes post-doseNormalized score at 60 minutes post-doseNormalized score at 90 minutes post-doseNormalized score at 120 minutes post-doseNormalized score at 150 minutes post-doseNormalized score at 180 minutes post-doseNormalized score at 240 minutes post-doseNormalized score at 360 minutes post-dose
64 mg/kg 1-Octanol Cellulose-based (CEL) Formulation11.0090.8260.7860.6700.6620.6800.6450.7910.894
64 mg/kg 1-Octanol Soybean Oil Embedded (SOY) Formulation10.9010.7380.7660.6850.7090.7460.7070.6830.122

PR and QTc Intervals Post 1-Octanol Dose

(NCT00102596)
Timeframe: 0 minutes, 15 minutes, 100 minutes and 24 hours post-dose

Interventionms (Least Squares Mean)
PR Interval at 0 minPR Interval at 15 minPR Interval at 100 minPR Interval at 24 hoursQTc Interval at 0 minQTc Interval at 15 minQTc Interval at 100 minQTc Interval at 24 hours
1-Octanol Dose168.8172.8171.6168.6433.8436.5433.0437.4

Auditory-perceptual Tremor Severity Ratings

Three experienced listeners independently rated each participant's voice from paired sample recordings comparing the baseline to post-test samples in randomized order for each condition. Sustained vowel and sentence-level recordings were rated, with decoded samples later analyzed for 1=better for post-test compared to baseline, 0= no difference between post-test and baseline. Maximum score for each participant was 3 (post-test was better for each of three raters). The range of possible scores was the sum of each of three raters' scores (0 to 3), with 0 indicating no difference between baseline and post-test voice tremor severity rating, and 3 indicating better voice (less tremor severity) at post-testing compared to pre-testing. Mean post-test values for task were compared for the octanoic acid and placebo conditions, and all raters were blind to which sample was a baseline versus a post-test recording, and which samples were associated with the [placebo or octanoic acid conditions. (NCT01864525)
Timeframe: Measured at baseline visits (1 & 2) and after 3 weeks of placebo or octanoic acid on post-test visits (1 & 2).

,
Interventionunits on a scale (Mean)
Sustained vowel, summed binary ratings (0-3)Sentence-level, summed binary ratings (0-3)
Octanoic Acid1.531.19
Placebo1.251.63

Magnitude of Acoustic Amplitude Tremor and Magnitude of Acoustic Frequency Tremor

Voice recordings were used to measure the degree of tremor in the voice. Mean post-test values for each acoustic measure were compared after the octanoic acid and placebo conditions, with and without consideration of baseline values. Mean values represent the average of two testing days. Degree of amplitude tremor shows the extent of amplitude variation as a percent of the mean signal amplitude, with lower numbers indicating less amplitude tremor. Baseline values for magnitude of amplitude tremor across all participants and conditions ranged from 4.06 to 27.09, and post-test values ranged from 1.94 to 26.02. Degree of frequency tremor shows the extent of fundamental frequency variation as a percent of the mean signal frequency, with lower numbers indicating less frequency tremor. Baseline values for magnitude of frequency tremor across all participants and conditions ranged from 1.21 to 15.31, and post-test values ranged from 0.60 to 13.86. (NCT01864525)
Timeframe: Measured at baseline visits (1 & 2) and after 3 weeks of placebo or octanoic acid on post-test visits (1 & 2)

,
Interventionpercentage of voice signal with tremor (Mean)
Baseline Magnitude of Acoustic Amplitude TremorPost-test Magnitude of Acoustic Amplitude TremorBaseline Magnitude of Acoustic Frequency TremorPost-test Magnitude of Acoustic Frequency Tremor
Octanoic Acid13.499.355.193.98
Placebo12.9112.435.575.35

Trials

3 trials available for 1-octanol and Essential Tremor

ArticleYear
An open-label, single-dose, crossover study of the pharmacokinetics and metabolism of two oral formulations of 1-octanol in patients with essential tremor.
    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2011, Volume: 8, Issue:4

    Topics: 1-Octanol; Administration, Oral; Aged; Caprylates; Chemistry, Pharmaceutical; Cross-Over Studies; Do

2011
An open-label, single-dose, crossover study of the pharmacokinetics and metabolism of two oral formulations of 1-octanol in patients with essential tremor.
    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2011, Volume: 8, Issue:4

    Topics: 1-Octanol; Administration, Oral; Aged; Caprylates; Chemistry, Pharmaceutical; Cross-Over Studies; Do

2011
An open-label, single-dose, crossover study of the pharmacokinetics and metabolism of two oral formulations of 1-octanol in patients with essential tremor.
    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2011, Volume: 8, Issue:4

    Topics: 1-Octanol; Administration, Oral; Aged; Caprylates; Chemistry, Pharmaceutical; Cross-Over Studies; Do

2011
An open-label, single-dose, crossover study of the pharmacokinetics and metabolism of two oral formulations of 1-octanol in patients with essential tremor.
    Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2011, Volume: 8, Issue:4

    Topics: 1-Octanol; Administration, Oral; Aged; Caprylates; Chemistry, Pharmaceutical; Cross-Over Studies; Do

2011
Pilot trial of 1-octanol in essential tremor.
    Neurology, 2004, Jan-13, Volume: 62, Issue:1

    Topics: 1-Octanol; Adult; Aged; Diagnostic Techniques, Neurological; Essential Tremor; Female; Humans; Male;

2004
Pilot trial of 1-octanol in essential tremor.
    Neurology, 2004, Jan-13, Volume: 62, Issue:1

    Topics: 1-Octanol; Adult; Aged; Diagnostic Techniques, Neurological; Essential Tremor; Female; Humans; Male;

2004
Pilot trial of 1-octanol in essential tremor.
    Neurology, 2004, Jan-13, Volume: 62, Issue:1

    Topics: 1-Octanol; Adult; Aged; Diagnostic Techniques, Neurological; Essential Tremor; Female; Humans; Male;

2004
Pilot trial of 1-octanol in essential tremor.
    Neurology, 2004, Jan-13, Volume: 62, Issue:1

    Topics: 1-Octanol; Adult; Aged; Diagnostic Techniques, Neurological; Essential Tremor; Female; Humans; Male;

2004
Open-label dose-escalation study of oral 1-octanol in patients with essential tremor.
    Neurology, 2004, Jun-22, Volume: 62, Issue:12

    Topics: 1-Octanol; Adult; Aged; Aged, 80 and over; Drugs, Investigational; Essential Tremor; Humans; Middle

2004

Other Studies

1 other study available for 1-octanol and Essential Tremor

ArticleYear
Carbenoxolone and mefloquine suppress tremor in the harmaline mouse model of essential tremor.
    Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:10

    Topics: 1-Octanol; Animals; Carbenoxolone; Central Nervous System Stimulants; Cerebellum; Chloroquine; Conne

2006